Celldex Therapeutics, Inc.

CLDX Nasdaq CIK: 0000744218

Company Information

Industry In Vitro & In Vivo Diagnostic Substances
SIC Code 2835
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 53 FRONTAGE ROAD, HAMPTON, NJ, 08827
Mailing Address 53 FRONTAGE ROAD, HAMPTON, NJ, 08827
Phone 908-200-7500
Fiscal Year End 1231
EIN 133191702

Financial Overview

FY2024

$792.34M
Total Assets
$34.81M
Cash & Equivalents
$-2.40
EPS

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment February 10, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 9, 2026 View on SEC
4 Insider stock transaction report January 6, 2026 View on SEC
4 Insider stock transaction report December 17, 2025 View on SEC
4 Insider stock transaction report December 8, 2025 View on SEC
4 Insider stock transaction report November 17, 2025 View on SEC
SCHEDULE 13G/A Passive ownership amendment November 14, 2025 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) November 14, 2025 View on SEC
SCHEDULE 13G/A Passive ownership amendment November 14, 2025 View on SEC
4 Insider stock transaction report November 12, 2025 View on SEC

Insider Trading

SELL 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2835)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.